'For the quarter ending Sept 2021, Net sales (including other operating income) of Glenmark Pharmaceuticals has increased 6.60% to Rs 3147.45 crore compared to quarter ended sept 2020.
Operating profit margin has jumped from 18.72% to 18.75%, leading to 6.76% rise in operating profit to Rs 590.18 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 28.13% to 27.10%. Purchase of finished goods cost fell from 9.68% to 9.11%. Employee cost decreased from 22.78% to 21.88%. Other expenses rose from 21.43% to 23.12%.
Other income rose 59% to Rs -13.07 crore. PBIDT rose 10.78% to Rs 577.11 crore. Provision for interest fell 14.49% to Rs 68.95 crore. Loan funds rose to Rs 3,896.89 crore as of 30 September 2021 from Rs 2,958.62 crore as of 30 September 2020. Inventories rose to Rs 2,531.00 crore as of 30 September 2021 from Rs 2,202...
Pleaselogin & subscribe to view the full report.
More Reports
|
|